McLean researchers awarded allowance for a method to treat PTSD and other disorders with xenon gas
McLean Hospital News Jul 13, 2017
Researchers from McLean Hospital have been issued a patent allowance for their invention involving the use of xenon gas to aid in the treatment of addiction and anxiety disorders such as post–traumatic stress disorder (PTSD). The allowance indicates that, pending administrative actions, a patent will be issued to Edward G. Meloni, PhD, an investigator in the Behavioral Genetics Laboratory at McLean Hospital and an assistant professor of psychiatry at Harvard Medical School and Marc J. Kaufman, PhD, director of the Translational Imaging Laboratory at McLean Hospital and an associate professor of psychiatry at Harvard Medical School.
The researchers found in an animal study that xenon gas works to block Âreconsolidation, a memory process in which recalled memories are susceptible to modification. Blocking this process lessens the emotional impact of the memory of the traumatic event. According to Meloni, Âthe invention may supplement traditional cognitive therapy or Âtalk therapy with xenon gas administered to help PTSD patients cope better with their traumatic memories.Â
Meloni explained that the invention could be used during a psychotherapy session in a clinicianÂs office. When talk therapy reactivates a traumatic memory, the patient would inhale the gas, which Âwill interfere with a neurobiological process that re–stores or Âreconsolidates the memory back into the brain.Â
Meloni said the he believes the invention will mostly be used in clinical settings, Âbut we also envision having patients be able to self–administer the gas through a portable inhalation device when they experience flashbacks, cues that trigger the traumatic memory, or nightmares – all common symptoms of PTSD.Â
Nobilis Therapeutics, a biotechnology company that develops inhalation–based treatments using inert gases, has licensed the patent. Nobilis is developing a hand–held medical device for self–administration of xenon outside of the clinicianÂs office, and is working to advance the use of the invention to treat patient populations with neurological and psychiatric disorders beyond PTSD.
Go to Original
The researchers found in an animal study that xenon gas works to block Âreconsolidation, a memory process in which recalled memories are susceptible to modification. Blocking this process lessens the emotional impact of the memory of the traumatic event. According to Meloni, Âthe invention may supplement traditional cognitive therapy or Âtalk therapy with xenon gas administered to help PTSD patients cope better with their traumatic memories.Â
Meloni explained that the invention could be used during a psychotherapy session in a clinicianÂs office. When talk therapy reactivates a traumatic memory, the patient would inhale the gas, which Âwill interfere with a neurobiological process that re–stores or Âreconsolidates the memory back into the brain.Â
Meloni said the he believes the invention will mostly be used in clinical settings, Âbut we also envision having patients be able to self–administer the gas through a portable inhalation device when they experience flashbacks, cues that trigger the traumatic memory, or nightmares – all common symptoms of PTSD.Â
Nobilis Therapeutics, a biotechnology company that develops inhalation–based treatments using inert gases, has licensed the patent. Nobilis is developing a hand–held medical device for self–administration of xenon outside of the clinicianÂs office, and is working to advance the use of the invention to treat patient populations with neurological and psychiatric disorders beyond PTSD.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries